TransMedics Group Stock Forecast, Price & News

-0.08 (-0.28 %)
(As of 07/27/2021 04:50 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume168,071 shs
Average Volume612,111 shs
Market Capitalization$796.12 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TMDX News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TransMedics Group logo

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.76 out of 5 stars

Medical Sector

487th out of 2,218 stocks

Electromedical Equipment Industry

9th out of 65 stocks

Analyst Opinion: 3.3Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions

Is TransMedics Group a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TransMedics Group stock.
View analyst ratings for TransMedics Group
or view top-rated stocks.

What stocks does MarketBeat like better than TransMedics Group?

Wall Street analysts have given TransMedics Group a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TransMedics Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting TransMedics Group?

TransMedics Group saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 1,320,000 shares, a decline of 14.3% from the June 30th total of 1,540,000 shares. Based on an average daily volume of 382,800 shares, the short-interest ratio is currently 3.4 days. Currently, 5.3% of the company's stock are short sold.
View TransMedics Group's Short Interest

When is TransMedics Group's next earnings date?

TransMedics Group is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for TransMedics Group

How can I listen to TransMedics Group's earnings call?

TransMedics Group will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) announced its quarterly earnings results on Tuesday, May, 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.01. The firm earned $7.05 million during the quarter, compared to analyst estimates of $6.93 million. TransMedics Group had a negative net margin of 110.54% and a negative trailing twelve-month return on equity of 26.18%.
View TransMedics Group's earnings history

How has TransMedics Group's stock been impacted by Coronavirus?

TransMedics Group's stock was trading at $13.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TMDX shares have increased by 111.5% and is now trading at $28.80.
View which stocks have been most impacted by COVID-19

What price target have analysts set for TMDX?

5 analysts have issued 12 month price targets for TransMedics Group's stock. Their forecasts range from $15.00 to $79.00. On average, they expect TransMedics Group's stock price to reach $45.40 in the next year. This suggests a possible upside of 57.6% from the stock's current price.
View analysts' price targets for TransMedics Group
or view top-rated stocks among Wall Street analysts.

Who are TransMedics Group's key executives?

TransMedics Group's management team includes the following people:
  • Dr. Waleed H. Hassanein, Founder, MD, CEO, Pres & Director (Age 53, Pay $939.73k)
  • Mr. Stephen Gordon, CFO. Treasurer & Sec. (Age 53, Pay $512.34k)
  • Dr. Tamer I. Khayal, Chief Commercial Officer (Age 52, Pay $533.69k)
  • Mr. John F. Carey, VP of Operations (Age 56)
  • Mr. Ike Okonkwo, VP of Fin. & Accounting (Age 50)
  • Mr. Mark Anderson, Sr. Director of Technology Devel.
  • Ms. Susan Goodman, VP of HR

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group CEO Waleed Hassanein on Waleed Hassanein has an approval rating of 83% among TransMedics Group's employees.

Who are some of TransMedics Group's key competitors?

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and The Walt Disney (DIS).

When did TransMedics Group IPO?

(TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

How do I buy shares of TransMedics Group?

Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $28.80.

How much money does TransMedics Group make?

TransMedics Group has a market capitalization of $795.46 million and generates $25.64 million in revenue each year. The company earns $-28,750,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does TransMedics Group have?

TransMedics Group employs 110 workers across the globe.

What is TransMedics Group's official website?

The official website for TransMedics Group is

Where are TransMedics Group's headquarters?

TransMedics Group is headquartered at 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.